Glaucoma 360 approaches disease from every angle
November 15th 2016Research. Industry. Philanthropy. These three facets-each with a unique purpose-will come together for the 2017 installment of the annual Glaucoma Research Foundation (GRF) Glaucoma 360 meeting. The three-day event will occur Feb. 2 to 4, 2016.
Taking stock of inventory control
November 15th 2016Despite growing profits over a decade, an ophthalmic practice’s optical dispensary profits were not growing along the same curve. This case study highlights how an optical dispensary inventory management firm may be able to identify strategies to boost capture-rate underperformance.
Toric trifocal IOL brings expanded range of functional vision to larger patient population
November 1st 2016Trifocal IOLs can provide good uncorrected vision at near, intermediate, and far. Outcomes in a series of 30 patients show that a toric version of a trifocal IOL (AT Lisa tri 939MP, Carl Zeiss Meditec) delivers those benefits for patients with > 1 D of corneal astigmatism.
Re-bubbling cases show a higher endothelial cell loss post-DMEK
November 1st 2016Analyses of data from 293 eyes undergoing uncomplicated Descemet membrane endothelial keratoplasty (DMEK) show that endothelial cell loss is greater in eyes that undergo a single re-bubbling for graft separation. The study, however, does not establish a causal association.
New dry eye treatment demonstrates rapid onset symptomatic relief
November 1st 2016Results from the Phase 3 OPUS-3 trial provide evidence confirming a benefit of lifitegrast ophthalmic solution 5.0% (Xiidra, Shire) for significantly improving dry eye disease-related symptoms, as measured by Eye Dryness Score.
Are we ophthalmologists in the eye of the storm?
November 1st 2016This meteorological phenomenon is considered to have given rise to one of the most commonly misused phrases in the English language. Some people think the phrase means that the situation is a tumultuous one, as when The Economist magazine reported: “French bank shares, which have been in the eye of the storm, recovered sharply (BNP Paribas was up 13% on the day while Societe Generale rose by 5%).”
Semifluorinated alkane technology brings advantages for topical therapy
November 1st 2016Semifluorinated alkane technology has novel physicochemical properties that explain its benefits as an ocular lubricant and support its use for developing a well-tolerated, preservative-free, multidose preparation of cyclosporine.
Bowman layer transplantation effective in advanced keratoconus
November 1st 2016Isolated Bowman layer transplantation can reduce and stabilize corneal ectasia in eyes with progressive advanced keratoconus, researchers said. “It flattens the cornea into a more normal position,” said Jack Parker, MD, a researcher at the Netherlands Institute for Innovative Ocular Surgery (NIIOS) in Rotterdam, The Netherlands. “It doesn’t give them perfect vision, but it keeps them from getting worse. It lets them to continue wearing their contact lenses.”
Time for a paradigm shift in the treatment of DME
October 21st 2016Well tolerated and effective, anti-VEGF therapy is the current gold standard to treat DME. However, one treatment simply does not fit all and VEGF may just be one piece of a much larger puzzle. The fact that some DME patients have a limited response to anti-VEGF therapy is representative of this concept; we are discovering that there are additional inflammatory mediators that may be crucial components to the DME picture.
What to do when the rhexis won’t tear
October 21st 2016Metabolic insult from silicone oil exposure can cause lens epithelial cells to undergo fibrous metaplasia, making the lens capsule resistant to tearing. Instead of persisting in trying to initiate a tear, surgeons should use an instrument to cut through the fibrotic material. This non-standard approach for opening the capsule recognizes potential for capsular fibrosis in eyes filled with silicone oil.
Managing the growing burden of glaucoma
October 17th 2016The number of patients with glaucoma will rise dramatically in the future because of growth in both the size of the aged population and in demographic groups at high-risk for the disease. Ophthalmology, however, is not equipped to handle the increasing demand for services considering workforce projections and current models of care.
Accelerated CXL rivals conventional technique
October 17th 2016Results from 2 years of follow-up in a large, prospective comparative study show that conventional corneal crosslinking (C-CXL) and accelerated CXL (A-CXL) are similarly safe and effective for stabilizing keratoconus progression in eyes with mild-to-moderate disease, said Tulika Chauhan, MD, at AAO 2016.
Improving the prognosis of uveal melanoma
October 16th 2016About one-half of people diagnosed with uveal melanoma ultimately develop metastatic disease. A look at survival rates for patients with uveal melanoma indicate that not much has changed in the past several decades or even for the past 100-plus years. Nevertheless, there is good reason to be optimistic about the future considering the recent developments and ongoing research in this field, said Mary Beth Aronow, MD, at Ocular Oncology and Pathology 2016.